Search / Trial NCT06616389

Study of ODX (OsteoDex) in Multiple Myeloma

Launched by DEXTECH MEDICAL AB · Sep 24, 2024

Apply for Trial

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * 1. Subject (male or female) is ≥ 18 years of age at the time of signing the informed consent form (ICF).
  • 2. Documented diagnosis av multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria.
  • 3. Measurable disease defined as either:
  • * Serum monoclonal paraprotein (M-protein) level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or
  • * Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
  • 4. Subjects must have received 1-5 prior lines of therapy including a PI, IMiD and CD38 antibody\*.
  • \*Patients eligible for inclusion should have received said treatments, i.e., according to clinical routine, unless contraindicated due to induced morbidity.
  • 5. Subjects must have documented evidence of progressive disease based on the IMWG criteria on or after their last line of therapy.
  • 6. Performance status ECOG 0-2 7. Laboratory requirements:
  • Haematology:
  • Neutrophils ≥ 1.0 x 109/l Hemoglobin ≥ 80 g/l Platelets ≥ 50 x 109/l
  • Hepatic function:
  • Total S/P-bilirubin ≤ 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN
  • Renal function:
  • S/P-creatinine ≤ 1.5 times ULN
  • Electrolytes:
  • S/P-sodium, S/P-potassium, S/P-calcium corrected for S/P albumin , S/P-phosphate, and S/P magnesium, all within normal ranges. At the discretion of the Investigator, supplements may be given to correct these values, in which case electrolytes must be shown to be within normal ranges before inclusion into the study.
  • 8. No evidence (\< 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin).
  • 9. Able to adhere to the study visit schedule and other protocol requirements.
  • Exclusion Criteria:
  • 1. Concurrent use of other anti-cancer agents/treatments.
  • 2. Any treatment modalities involving chemotherapy, radiation, or major surgery within 4 weeks prior to treatment in this study.
  • 3. Simultaneous participation in any other study involving investigational drugs or having participated in an investigational study less than 4 weeks prior to start of study treatment.
  • 4. Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he or she participates in the study.
  • 5. Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
  • 6. Plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome.
  • 7. Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug.
  • 8. Treatment with bisphosphonates or denosumab within 6 weeks prior to first dose of study medication.
  • 9. Male subjects not willing to use condom to prevent pregnancy and drug exposure of a fertile female partner and refrain from donating sperm from the date of the first dose until the end of study treatment.
  • 10. Pregnant or breastfeeding females.
  • 11. Female subjects of childbearing potential\*\* not willing to use a contraceptive method with a failure rate of \< 1% to prevent pregnancy during study treatment. Highly effective birth control methods include:
  • * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
  • * oral
  • * intravaginal
  • * transdermal
  • * progestogen-only hormonal contraception associated with inhibition of ovulation:
  • * oral
  • * injectable
  • * implantable
  • * intrauterine device
  • * intrauterine hormone-releasing system (for example, progestin-releasing coil)
  • * vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate)
  • * bilateral tubal occlusion or hysterectomy. \*\*Female subjects are considered of non-childbearing potential if they are pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as at least 12 months of amenorrhea.
  • 12. Subjects in which pre-medication with dexamethasone, antihistamine, and paracetamol would be contraindicated.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Stockholm, , Sweden

Uddevalla, , Sweden

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0